Key facts
- This page summarizes Garry E. Menzel's Form 4 filing for TCR2 THERAPEUTICS INC..
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2021, 15:32.
Garry E. Menzel - 31 Aug 2021 Form 4 Insider Report for TCR2 THERAPEUTICS INC.
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 31 Aug 2021
- Net transaction value
- +$265,018
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2021, 15:32:50 UTC
- Prior SEC filing
- 22 Jun 2021
- Next SEC filing
- 18 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Margaret Siegel as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Garry E. Menzel filed Form 4 for TCR2 THERAPEUTICS INC. on 10 Dec 2021.
Change
- Previous filing in this sequence was filed on 22 Jun 2021.
- Current net transaction value: +$265,018.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCRR
transaction
Common Stock
Award
- Transaction value
- $6,018
- Shares
- +422
- Change %
- +10%
- Price
- $14.26*
- Shares after
- 4,507
- Date
- 31 Aug 2021
- Ownership
- Direct
- Footnotes
- F2, F3
TCRR
transaction
Common Stock
Options Exercise
- Transaction value
- $129,500
- Shares
- +175,000
- Change %
- +3883%
- Price
- $0.7400
- Shares after
- 179,507
- Date
- 09 Dec 2021
- Ownership
- Direct
TCRR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 84,527
- Date
- 31 Aug 2021
- Ownership
- See Footnote
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TCRR
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $125,100
- Shares
- +169,054
- Change %
- Price
- $0.7400
- Shares after
- 0
- Date
- 10 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 169,054
- Exercise price
- $0.7400
- Footnotes
- F4
TCRR
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $4,400
- Shares
- +5,946
- Change %
- +4.5%
- Price
- $0.7400
- Shares after
- 138,031
- Date
- 10 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,946
- Exercise price
- $0.7400
- Footnotes
- F5
TCRR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +305,800
- Change %
- Price
- $0.000000
- Shares after
- 305,800
- Date
- 09 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 305,800
- Exercise price
- $5.21
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Consists of 84,527 shares of common stock held by Dr. Garry Menzel, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010. Dr. Menzel is the trustee of the Garry E. Menzel and Mary E. Henshall Family Trust and may be deemed to beneficially own these securities.
Footnote F2
The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2021 through August 31, 2021. This transaction is exempt under Rule 16b-3(c).
Footnote F3
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on August 31, 2021.
Footnote F4
The Reporting Person was granted an option to purchase 253,581 shares on December 13, 2016. 84,527 of such options were previously exercised. 25% of this option vested and became exercisable on October 17, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
Footnote F5
25% of this option vested and became exercisable on December 6, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
Footnote F6
25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter